| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 3.276 | 25.747 | 23.683 | 18.443 | 27.411 | 37.594 | 32.837 | 0 |
| Total Income - EUR | - | - | 3.276 | 26.350 | 23.696 | 20.170 | 27.431 | 37.595 | 32.837 | 0 |
| Total Expenses - EUR | - | - | 5.360 | 23.024 | 24.008 | 19.305 | 22.852 | 28.150 | 31.873 | 0 |
| Gross Profit/Loss - EUR | - | - | -2.084 | 3.326 | -312 | 865 | 4.578 | 9.446 | 964 | 0 |
| Net Profit/Loss - EUR | - | - | -2.117 | 3.068 | -549 | 694 | 4.337 | 9.126 | 651 | 0 |
| Employees | - | - | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 |
Check the financial reports for the company - Dualbio Product S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 2.839 | 2.320 | 1.818 | 1.334 | 866 | 428 | 112 | 0 |
| Current Assets | - | - | 2.556 | 2.324 | 3.550 | 9.710 | 13.797 | 16.363 | 17.492 | 0 |
| Inventories | - | - | 2.411 | 2.305 | 2.260 | 2.221 | 2.187 | 1.859 | 1.853 | 0 |
| Receivables | - | - | 0 | 0 | 671 | 464 | 647 | 374 | 372 | 0 |
| Cash | - | - | 145 | 20 | 619 | 7.024 | 10.962 | 14.131 | 15.267 | 0 |
| Shareholders Funds | - | - | -2.073 | 1.033 | 464 | 1.149 | 5.461 | 14.604 | 15.211 | 0 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 0 |
| Debts | - | - | 7.468 | 3.612 | 4.904 | 9.895 | 9.202 | 2.187 | 2.394 | 0 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "5610 - 5610" | |||||||||
| CAEN Financial Year |
5610
|
|||||||||
Comments - Dualbio Product S.r.l.